Predictive biomarkers of response to bacillus Calmette‐Guérin immunotherapy and bacillus Calmette‐Guérin failure for non‐muscle invasive bladder cancer

Wang, Ziting; So, Wei Zheng; Loh, Kep Yong; Lim, Y.C.; Mahendran, Ratha; Wu, Qing; Chiong, Edmund

doi:10.1111/iju.14921

Cited by 3 publications

(2 citation statements)

References 66 publications

(112 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Those tumors also exhibit high microsatellite instability (MSI-H), a predictive biomarker for those therapies [ 15 , 16 ]. Pembrolizumab has been approved as a treatment option for BCG-unresponsive NMIBC with in situ characteristics,[ 17 ] even without a predictive response biomarker [ 18 , 19 ]. However, there are several other non-canonic immune checkpoints unexplored, their knowledge in bladder cancer is still limited, and they might represent risk-stratified biomarkers or even new and promising targets for therapy [ 20 , 21 ].…”

Section: Introductionmentioning

confidence: 99%

Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer

Zucca,

Laus,

Sorroche

et al. 2024

Translational Oncology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer

Zucca,

Laus,

Sorroche

et al. 2024

Translational Oncology

View full text Add to dashboard Cite

“…To improve stratification for better immunotherapeutic applications, numerous studies have paid great attention to biomarker identification for response to ICIs ( 3 , 8 , 11 – 15 ). Attempts to look for BCG treatment predictors are far behind, and the evaluation of BCG response depends mainly on cystoscopy, cytology and/or bladder biopsy nowadays ( 8 ), although several molecules are shown to serve as potential factors ( 16 ). In short, searching for reliable prognostic factors for patient survival, recurrence, NMIBC progression to MIBCs and treatment response are critical unmet needs, and patients with high-risk can thus be pinpointed for active surveillance and personalized intervention, thereby reducing BLCA-associated morbidity and mortality.…”

Section: Introductionmentioning

confidence: 99%

The cuproptosis-associated 11 gene signature as a predictor for outcomes and response to Bacillus Calmette-Guerin and immune checkpoint inhibitor therapies in bladder carcinoma

et al. 2023

View full text Add to dashboard Cite

Bladder cancer (BC) or carcinoma (BLCA) is predominantly derived from urothelium and includes non-muscle invasive BC (NMIBC) and muscle invasive BC (MIBC). Bacillus Calmette-Guerin (BCG) has long been applied for NMIBC to effectively reduce disease recurrence or progression, whereas immune checkpoint inhibitors (ICIs) were recently introduced to treat advanced BLCA with good efficacy. For BCG and ICI applications, reliable biomarkers are required to stratify potential responders for better personalized interventions, and ideally, they can replace or reduce invasive examinations such as cystoscopy in monitoring treatment efficacy. Here we developed the cuproptosis-associated 11 gene signature (CuAGS-11) model to accurately predict survival and response to BCG and ICI regimens in BLCA patients. In both discovery and validation cohorts where BLCA patients were divided into high- and low-risk groups based on a median CuAGS-11 score as the cutoff, the high-risk group was associated with significantly shortened overall survival (OS) and progression-free survival (PFS) independently. The survival predictive accuracy was comparable between CuAGS-11 and stage, and their combination-based nomograms showed high consistence between predicted and observed OS/PFS. The analysis of 3 BLCA cohorts treated with BCG unveiled lower response rates and higher frequencies of recurrence or progression coupled with shorter survival in CuAGS-11 high-risk groups. In contrast, almost none of patients underwent progression in low-risk groups. In IMvigor210 cohort of 298 BLCA patients treated with ICI Atezolizumab, complete/partial remissions were 3-fold higher accompanied by significantly longer OS in the CuAGS-11 low- than high-risk groups (P = 7.018E-06). Very similar results were obtained from the validation cohort (P = 8.65E-05). Further analyses of Tumor Immune Dysfunction and Exclusion (TIDE) scores revealed that CuAGS-11 high-risk groups displayed robustly higher T cell exclusion scores in both discovery (P = 1.96E-05) and validation (P = 0.008) cohorts. Collectively, the CuAGS-11 score model is a useful predictor for OS/PFS and BCG/ICI efficacy in BLCA patients. For BCG-treated patients, reduced invasive examinations are suggested for monitoring the CuAGS-11 low-risk patients. The present findings thus provide a framework to improve BLCA patient stratification for personalized interventions and to reduce invasive monitoring inspections.

show abstract

Tumor Biomarkers for Bacillus Calmette-Guérin Response: What We Get Is Not What We Want

Sjödahl

Bernardo

Eriksson

et al. 2023

European Urology Focus

View full text Add to dashboard Cite

Predictive biomarkers of response to bacillus Calmette‐Guérin immunotherapy and bacillus Calmette‐Guérin failure for non‐muscle invasive bladder cancer

Cited by 3 publications

References 66 publications

Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer

Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer

The cuproptosis-associated 11 gene signature as a predictor for outcomes and response to Bacillus Calmette-Guerin and immune checkpoint inhibitor therapies in bladder carcinoma

Tumor Biomarkers for Bacillus Calmette-Guérin Response: What We Get Is Not What We Want

Contact Info

Product

Resources

About